Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
Portfolio Pulse from Benzinga Newsdesk
Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
July 25, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectis shares are trading higher following the FDA's grant of orphan drug and rare pediatric designation to UCART22.
The FDA's grant of orphan drug and rare pediatric designation to UCART22 is a significant regulatory milestone for Cellectis. This designation can provide market exclusivity, tax credits, and other benefits, which are likely to positively impact the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100